Theravance, Inc.

National Research Council of Canada

Trevor Mischki

Mathai Mammen

Adam D Hughes

Craig Husfeld

Yu-Hua Ji

Li Li

Sarah Dunham

YongQi Mu

Eric L Stangeland

Yuhua Ji

Aaron Kushner

Richard D Wilson

Ioanna Stergiades

Viengkham Malathong

David A Oare

Yan Chen

Siegfried Janz

Dan-Xia Xu

Adam Densmore

Jens Schmid

Daniel Poitras

Jean Lapointe

Philip Waldron

Greg Lopinski

Bill Sinclair

A technique for high sensitivity evanescent field molecular sensing employs a detection scheme that simultaneously couples a polarized beam to a single mode of a waveguide, and couples the polarized beam out of the waveguide to specularly reflect the beam by the same grating. Strong interaction with the single (preferably TM) mode is provided by using a silicon on insulator (SOI) wafer having a waveguide thickness chosen between 10-400 nm so that the majority of the mode field strength spans the evanescent field. Well known, robust techniques for producing a grating on the waveguide are provided. Interrogation from a backside of the SOI wafer is taught.

Grating-based evanescent field molecular sensor using a thin silicon waveguide layer

The invention provides compounds of formula I: wherein a, b, c, m, s, t, W, Z, Ar, R, R, R, R, and Rare as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Biphenyl compounds useful as muscarinic receptor antagonists

This invention provides compounds of formula I: 

[object Object]

This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

Substituted 4-amino-benzylpiperidine compounds

This invention provides compounds of formula I: wherein a, b, c, m, p, s, t, W, Ar, X, R, R, R, R, R, and Rareas defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention provides compounds of formula I: wherein a, b, c, m, p, s, t, W, Ar, X, R, R, R, R, R, and Rare as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Substituted 4-amino-1-benzylpiperidine compounds

This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.

Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds

Growing community of inventors

Ottawa, Canada

Trevor Mischki